Cipla Reports Q1 FY27 Results: Global Revenue Reaches INR 7,119 Cr

Cipla Reports Q1 FY27 Results: Global Revenue Reaches INR 7,119 Cr​

Mumbai, July 23, 2026: Cipla Limited today announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported global revenues of INR 7,119 Cr, with strong performance noted across various markets.

The One-India business recorded the highest quarterly sales, achieving a solid 12% year-on-year (YoY) growth. Globally, Cipla generated total income from operations of INR 7,119 Cr and reported an EBITDA of INR 1,192 Cr. The company maintained a net cash position of INR 9,494 Cr.

Business Segment Performance Highlights​

The performance across Cipla's key operating segments varied:

One India:

• Branded Prescription segment delivered market number growth of 15.4%, which was 183 basis points (bps) higher than IPM. The overall Chronic mix in this segment improved to 60.4%. Key therapies showing strong performance included Respiratory, Urology, Cardiac, and Anti-diabetes, all growing at double-digit market rates.
• Trade Generics recorded healthy YoY growth, supported by execution excellence in distribution and new introductions. During the quarter, three new products were launched in this category.
• Consumer Health segment saw anchor brands such as Nicotex, Omnigel, and Cipladine maintain their leadership positions.

North America:
The company generated quarterly revenue of $162 Mn from North America. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market with a 21% market share during the quarter. The business launched gVentolin following regulatory approval received last quarter, and commercial shipments have commenced with volumes expected to increase gradually as supply ramps up. Launches of Nintedanib and Dapagliflozin also expanded presence in high-growth therapy areas.

International Markets:

• One Africa: Prescription business maintained No. 2 position in the market, achieving a secondary growth rate of 6.5% against the market's 5.7% growth. Revenue for this segment was INR 977 Cr.
• Emerging Markets and Europe: This segment delivered a growth of 5% YoY in USD terms, attributed to the deep market focus strategy, with an uptick seen in both DTM and B2B categories, along with sustained overall margins. Revenues stood at INR 999 Cr for the quarter.
• South Africa: The business recorded revenues of INR 658 Cr, showing a decline of 5% compared to the previous period.

Research and Development:
R&D investments stood at INR 486 Cr, which accounted for 6.8% of sales and showed a 12.3% YoY increase, driven by increased product filings and development initiatives. The net cash position remains strong at INR 9,494 Cr; debt primarily relates to lease liabilities and working capital requirements.

Consolidated Financials Snapshot​

The quarterly financial results for Cipla Limited are summarized below:

Quarterly Business Wise Sales Performance (in INR Cr)


Consolidated Profit & Loss Statement (in INR Cr)


Balance Sheet Highlights (in INR Cr)

CEO Commentary​

Achin Gupta, MD and Global CEO of Cipla Ltd., stated that the company continues to make considerable progress across its focused markets. He noted that in Q1FY27, global revenues reached INR 7,119 Cr, with the One-India business showing a solid 12% YoY growth. The branded prescription business delivered robust growth, driven by key therapies outpacing the market, while Trade Generics experienced healthy growth.

Gupta added that the US business posted revenue of $162 Mn during the quarter, and he expressed confidence in continued sequential growth in North America, supported by the upcoming product pipeline. Furthermore, he highlighted that emerging markets and Europe maintained their growth trajectory with 5% YoY revenue increase in USD terms, underpinned by a deep market focus strategy. The company plans to continue focusing on growing key markets, building flagship brands, and investing in future pipelines while addressing regulatory resolutions.

CIPLA Stock Price Movement​

As of 12:49 PM, shares of Cipla Limited are shedding value in live trading, currently slipping by 2.35% to ₹1381.8. The stock has seen a substantial volume of nearly 2.4 million shares traded so far during the current market session.